Treatment of advanced lung cancer with HER2 mutations using SHR-A1811
Official title: A Randomized, Open-Label, Multicenter Phase III Study of SHR-A1811 for First-Line Treatment in Subjects With HER2-Mutated Advanced or Metastatic Non-Small Cell Lung Cancer
Run by Jiangsu HengRui Medicine Co., Ltd. · NCT06430437 · Data updated 2026-11-12
This study is testing a new treatment called SHR-A1811 to see if it works better than standard care for adults with advanced lung cancer that has specific HER2 mutations.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. Industry-sponsored |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Status | Recruiting |
| Started | July 29, 2024 |
| Main results expected | February 2026 |
| Study ends | April 2027 |
| Registry record updated | January 21, 2026 |
| Trial ID | NCT06430437 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18-75 with confirmed advanced or metastatic NSCLC and functional HER2 mutations who have not undergone prior systemic therapy.
✕Probably not a fit
Patients with mixed lung cancer types, other concurrent driver gene mutations, or untreated CNS metastases may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the efficacy and safety of SHR-A1811 compared to standard care for patients with advanced or metastatic non-small cell lung cancer (NSCLC) that has HER2 mutations. It is a Phase 3 interventional trial that includes patients aged 18-75 who have not received prior systemic therapy for their condition. Participants will receive either SHR-A1811 or standard treatments such as Camrelizumab, Pemetrexed/Paclitaxel, or Carboplatin/Cisplatin, with the aim of determining which approach provides better outcomes.
Why it matters
Potential benefit: If successful, this treatment could offer a new effective option for patients with advanced lung cancer harboring HER2 mutations.
How similar studies have gone: While there have been studies targeting HER2 mutations in lung cancer, the specific use of SHR-A1811 in this context is a novel approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Able and willing to provide a written informed consent 2. 18-75 years old (inclusive of both ends) 3. ECOG score of 0 or 1. 4. Patients with histologically or cytologically confirmed advanced or metastatic NSCLC. 5. Subjects with central laboratory- confirmed functional HER2 mutations 6. No prior systemic antitumor therapy (including investigational agents) for advanced or metastatic NSCLC. 7. Have at least one measurable lesion outside the central nervous system that meets the criteria defined by RECIST v1.1 8. Protocol-defined adequate organ function including cardiac, renal, hepatic function Exclusion Criteria: 1. Mixed lung cancer with small cell components and sarcomatoid carcinoma confirmed by histology or cytology. 2. Concurrently carrying other driver gene mutations, and targeted drugs for such driver gene mutations have been approved for market release. 3. Subjects with untreated or active metastasis of central nervous system (CNS) tumors, or a history of meningeal metastasis or current meningeal metastasis. 4. With poorly controlled tumor-related pain. 5. previous or current with other malignancies. 6. Subjects with a history of interstitial pneumonia/non-infectious pneumonia requiring hormone therapy, or current interstitial pneumonia/non-infectious pneumonia. 7. Subjects with active or previous autoimmune diseases. 8. Subjects with uncontrolled or severe cardiovascular diseases. 9. Subjects with active hepatitis B or hepatitis C.
Where it's running
-
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China Recruiting
Study contacts
- Study coordinator: You Li
- Email: you.li.yl1@hengrui.com
- Phone: 0518-81220121
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
HRS-7172 with other cancer drugs in advanced pancreatic cancer
This study tests if HRS-7172 added to standard cancer therapies can help people with advanced pancreatic cancer that has RAS mutations or amplifications.
-
FH-006 vs physician's choice chemotherapy for ESCC after PD-1/PD-L1 + platinum failure
This study tests whether FH-006 helps people with esophageal squamous cell carcinoma live longer than the physician’s choice second-line chemotherapy after prior PD-1/PD-L1 inhibitors with platinum have stopped working.
-
HRS-9190 vs Rocuronium for Muscle Relaxation During Anesthesia
This Phase 3 trial tests whether HRS-9190 can provide effective muscle relaxation for intubation and surgery as compared with rocuronium in adults undergoing elective general anesthesia.
-
HRS-7525 tablets in advanced prostate cancer
This study tests whether HRS-7525 tablets can be safely given to men with advanced prostate cancer and helps find a tolerable dose for future tests.
-
HRS-3005 in B-cell Malignancies
This early-phase study tests HRS-3005 in adults with relapsed or refractory B-cell cancers to see if it is safe and tolerable and to find a suitable dose for future studies.
-
Trastuzumab Rezetecan versus Trastuzumab Deruxtecan for unresectable HER2‑low, HR‑positive breast cancer
This Phase 2 trial tests different doses of Trastuzumab Rezetecan compared with Trastuzumab Deruxtecan in women with HR-positive, HER2-low unresectable locally recurrent or metastatic breast cancer to see which dose is safer and more effective.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.